PHOSP-COVID is jointly funded by a grant from the Medical Research Council UK Research and Innovation and the Department of Health and Social Care through the National Institute for Health Research (NIHR) rapid response panel to tackle COVID-19 (MR/V027859/1 and COV0319). The views expressed in the publication are those of the authors and not necessarily those of the National Health Service, the NIHR, or the Department of Health and Social Care. CEB has received grants to his institution and consulting fees from GSK, AstraZeneca, Sanofi, Regeneron, Roche, Genentech, Boehringer Ingelheim, Novartis, Chiesi, 4D Pharma, and Mologic; and consulting fees from Areteia. RAE reports research funding from the Wolfson Foundation and Genentec/Roche; consulting fees from AstraZeneca; speaker's fees from Boehringer Ingelheim and Moderna; support for attending meetings from Chiesi; and roles as European Respiratory Society Pulmonary Rehabilitation and Chronic Care committee Secretary and American Thoracic Society Pulmonary Rehabilitation Assembly Chair. LVW reports a professorship from GSK and Asthma + Lung UK; research funding from Orion Pharma, GSK, Genentech, AstraZeneca, Nordic Bioscience, and Sysmex (OGT); consulting fees from Galapagos, Boehringer Ingelheim, and GSK; support for a site visit from Genentech; participation on an advisory board for Galapagos; and roles as Associate Editor for the European Respiratory Journal and as board member and Deputy Chair at the Medical Research Council. AS and NS declare no competing interests.